Updated: A GPCR startup out of France and Canada scores its Series A after 14 years of wheeling and dealing

Paul Schloesser

Associate Editor

Having already nailed down multiple licensing and collaboration deals with Big Pharma giants like Bristol Myers Squibb and Pfizer, a France- and Quebec-based GPCR biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: A GPCR startup out of France and Canada scores its Series A after 14 years of wheeling and dealing

Paul Schloesser

Associate Editor

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

Jim Wilson's GemmaBio raises $34M to commercialize gene therapies for rare diseases

Up­dat­ed: A GPCR start­up out of France and Cana­da scores its Se­ries A af­ter 14 years of wheel­ing and deal­ing

Paul Schloesser

Associate Editor

Sign up to read this article for free.

more like this

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

Updated: A GPCR startup out of France and Canada scores its Series A after 14 years of wheeling and dealing

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

Jim Wilson's GemmaBio raises $34M to commercialize gene therapies for rare diseases